Karuna Therapeutics To $276? Plus SVB Leerink Almost Doubles Price Target On This Stock

  • Mizuho boosted the price target for Karuna Therapeutics, Inc. KRTX from $190 to $276. Karuna Therapeutics shares fell 1.3% to $238.00 in pre-market trading.
  • Needham lowered the price target on CorMedix Inc. CRMD from $20 to $12. CorMedix shares fell 55% to $3.38 in pre-market trading.
  • HC Wainwright & Co cut Aurinia Pharmaceuticals Inc. AUPH price target from $30 to $26. Aurinia Pharmaceuticals shares fell 1.2% to close at $8.27 on Monday.
  • Barclays cut the price target on CRISPR Therapeutics AG CRSP from $99 to $88. CRISPR Therapeutics shares fell 2.6% to $79.30 in pre-market trading.
  • Deutsche Bank lowered price target for Palantir Technologies Inc. PLTR from $11 to $8. Palantir Technologies shares fell 2.2% to $9.60 in pre-market trading.
  • SVB Leerink boosted the price target on Myovant Sciences Ltd. MYOV from $12 to $23. Myovant Sciences shares rose 1.5% to $15.91 in pre-market trading.
  • Keybanc cut the price target for ICU Medical, Inc. ICUI from $230 to $225. ICU Medical shares rose 4.7% to close at $188.10 on Monday.
  • Atlantic Equities cut the price target on Amgen Inc. AMGN from $190 to $182. Amgen fell 0.4% to $246.39 in pre-market trading.
  • BMO Capital cut the price target on Tyson Foods, Inc. TSN from $99 to $90. Tyson Foods shares rose 0.1% to $80.13 in pre-market trading.
  • Needham boosted the price target on CECO Environmental Corp. CECE from $9 to $11. CECO Environmental shares fell 1.2% to $8.91 in pre-market trading.

Don’t forget to check out our premarket coverage here .

Check out this: NVIDIA To $240? Here Are 5 Other Price Target Changes For Tuesday

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: NewsPrice TargetSmall CapPre-Market OutlookMarketsAnalyst RatingsPT Changes
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!